- [[Alan]]: I suspect we want to target Jonathan, Denise and Maria. Message around that things are ongoing and set a time to coming back and talking about the project. Not about meeting them all the time, but when we're in important stage gates so they're in the loop. Good idea when [[EMA]] is finalized. What's the process and the timeline and how do we handle the different variants. Two main questions to ask for timing.
- [[Ale]]: We need to understand the 9 and 8mg [[ivm]] are still in development. Are far from where the [[FDC]] is. But I think having them in the visual field might work in our benefit. Also, to see what the reaction is to those two products.
- [[Alan]]: Lets think [[ivm]]. If it's never going to be a commercial product it doesn't make sense to bring it on. We need to get their trust. It would be beneficial for the company to see if they have something in their goals to mean that 9mg and 18mg make sense beyond [[public health]].
-
- [[Ale]]: What do [[WHO]] wwant and need from us? They put our fdc similar to the triple thearpy for LF, but our project is very different.
- Julie: First off, they may all want to agree on the answer. I don't think
Borja FMS
3 months ago